Evaxion A/S (EVAX)
About Evaxion A/S
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $29.6M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $29.6M
- Shares outstanding
- 10.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 5, 2021
Evaxion A/S (EVAX) Stock Price
- Trading 73% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Evaxion A/S.
Write a review
News about Evaxion A/S
News & sentiment via Polygon.io
Evaxion A/S: frequently asked questions
Is Evaxion A/S an American company?
Evaxion A/S is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Evaxion A/S publicly traded?
Yes — Evaxion A/S is a publicly traded company. Its stock trades under the ticker symbol EVAX on the NASDAQ.
What does Evaxion A/S do?
Evaxion A/S is an American Pharmaceuticals company in the Health & Beauty sector.
